- Home
- GILD vs STX Comparison
GILD vs STX Comparison
Compare GILD & STX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | STX |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 181.5B |
| IPO Year | 2003 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GILD | STX |
|---|---|---|
| Price | $146.55 | $809.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 21 |
| Target Price | $148.39 | ★ $604.14 |
| AVG Volume (30 Days) | ★ 6.4M | 4.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.55% | 0.46% |
| EPS Growth | ★ 1684.21 | 105.32 |
| EPS | N/A | ★ 13.90 |
| Revenue | ★ $24,689,000,000.00 | $7,384,000,000.00 |
| Revenue This Year | $4.68 | $27.73 |
| Revenue Next Year | $6.04 | $25.06 |
| P/E Ratio | ★ N/A | $57.47 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $108.46 | $163.86 |
| 52 Week High | $157.29 | $1,145.00 |
Technical Indicators
Market Signals| Indicator | GILD | STX |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 45.89 |
| Support Level | $142.93 | $793.95 |
| Resistance Level | $149.38 | $841.31 |
| Average True Range (ATR) | 3.50 | 56.93 |
| MACD | 1.12 | -6.08 |
| Stochastic Oscillator | 91.85 | 22.92 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.